Pulmonary Arterial Hypertension: Pathophysiology and Treatment

Лёгочная артериальная гипертензия: патофизиология и лечение
Chim Choy Lang, Norris S. H. Lan, Benjamin D. Massam, Sandeep S. Kulkarni
2018-05-16

angioproliferative vasculopathyendothelin receptor antagonistsinitial combination therapypulmonary arterial hypertensionpulmonary vascular resistance
Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a chronic and progressive disorder characterised by angioproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation and thrombosis. These changes increase pulmonary vascular resistance and subsequent pulmonary arterial pressure, causing right ventricular failure which leads to eventual death if untreated. The management of PAH has advanced rapidly in recent years due to improved understanding of the condition's pathophysiology, specifically the nitric oxide, prostacyclin-thromboxane and endothelin-1 pathways. Five classes of drugs targeting these pathways are now available: phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, prostacyclin receptor agonists and endothelin receptor antagonists. These developments have led to substantial improvements in mortality rate in recent decades. Recently, long-term studies have demonstrated sustained progression-free survival and have created a new paradigm of initial combination therapy. Despite these targeted therapies, PAH is still associated with significant morbidity and mortality. As such, further research into broadening our understanding of PAH pathophysiology is underway with potential of increasing the repertoire of drugs available.
1
Advances in pathway-targeted therapy have substantially improved PAH mortality, while long-term studies show sustained progression-free survival and support initial combination therapy.
2
Despite therapeutic progress, PAH remains associated with substantial morbidity and mortality, motivating research into additional pathophysiological mechanisms and treatments.
3
Five targeted drug classes are available: phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, prostacyclin receptor agonists, and endothelin receptor antagonists.
4
PAH pathophysiology involves endothelial and smooth muscle dysfunction, inflammation, thrombosis, and dysregulation of nitric oxide, prostacyclin-thromboxane, and endothelin-1 pathways.
5
Pulmonary arterial hypertension is a chronic, progressive angioproliferative vasculopathy that increases pulmonary vascular resistance and can cause fatal right ventricular failure.

pulmonary arterial hypertension (PAH)

the pathophysiology, targeted treatment pathways, and clinical progression and outcomes of PAH

Publication Details
Publication Date
2018-05-16
Journal
Publisher
ISSN
Cited by
196
Access Type
Author Information
Authors
Chim Choy Lang
Norris S. H. Lan
Benjamin D. Massam
Sandeep S. Kulkarni
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%